Citations

Clear

4847 citation(s) found for "Tu, Eric".

The hope and the hype of artificial intelligence for syncope management
Johnston, Samuel L. , Barsotti, Ercole John , Fedorowski, Artur , Ricci, Fabrizio , Heller, Eric G, Sheldon, Robert S. , Sutton, Richard , Shen, Win‐Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H. , Aburizik, Arwa , Haselton, Corey R, Cuskey, Alex J, Johansson, Madeleine , Dominic, Paari , Rao, B. Hygriv , Mudireddy, Avinash , Statz, Giselle M., Benditt, David G. , Gatti, Mauro , Menè, Roberto , Shiffer, Dana , Vassilikos, Vassilios , Bakogiannis, Constantinos , Fedorowski, Artur , Ricci, Fabrizio , Sheldon, Robert , Sutton, Richard , Shen, Win-Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H , Aburizik, Arwa , Lee, Sangil , Johansson, Madeleine , Macfarlane, Donald , Dominic, Paari , Abe, Haruhiko , Rao, B Hygriv , Mudireddy, Avinash , Sonka, Milan , Sandhu, Roopinder K , Kenny, Rose Anne , Gopinathannair, Rakesh , Benditt, David , Dipaola, Franca , Gatti, Mauro , Giaj Levra, Alessandro , Furlan, Raffaello , Ruwald, Martin H , Vassilikos, Vassilios , Gebska, Milena A , Olshansky, Brian , Cuskey, Alex, Lee, Sangil , Kenny, Rose Anne , Gopinathannair, Rakesh , Dipaola, Franca , Costantino, Giorgio , Furlan, Raffaello , Olshansky, Brian

Mayo Clinic

European Heart Journal - Digital Health | June 25, 2025 | Volume: 6 | Issue: 5 | Pages: 1046-1054

10.1093/ehjdh/ztaf061 | PMID 40984999 Get It

Abstract Aims Syncope remains a diagnostic challenge despite advancements in testing and treatment. Cardiac syncope is an independent predictor of mortality and can be difficult to distinguish from other causes of transient loss of consciousness (TLOC). This paper explores whether artificial intelligence (AI) can improve the evaluation and management of patients with syncope. Methods and results We conducted a literature review and incorporated the opinions of experts in the fields of syncope and AI. The cause of TLOC is often unclear, hospitalization criteria are ambiguous, diagnostic tests are frequently non-informative, and assessments are costly. Patients are left with unanswered questions and limited guidance. Artificial intelligence (AI) has the potential to optimize syncope evaluation by processing large data sets, detecting imperceptible patterns, and assisting clinicians. However, AI has limitations, including errors, lack of human empathy, and uncertain clinical utility. Liability issues further complicate its integration. We present three viewpoints: (i) AI is crucial for advancing syncope management; (ii) AI can enhance the patient experience; and (iii) AI in syncope care is inevitable. Conclusion Artificial intelligence may improve syncope diagnosis and management, particularly through machine learning–based test interpretation and wearable device data. However, it has yet to surpass human clinical judgment in complex decision-making. Current challenges include gaps in understanding syncope mechanisms, AI interpretability, generalizability, and clinical integration. Standardized diagnostic approaches, real-world validation, and curated data sets are essential for progress. Artificial intelligence may enhance efficiency and communication but raises concerns regarding confidentiality, bias, inequities, and legal implications.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer
Russo, Suzanne , Anker, Christopher J. , Codipilly, Don C. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher L. , Kennedy, Timothy J., Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Jin, Zhaohui , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Small, William , Tchelebi, Leila T. , Simone, Charles B.

Mayo Clinic

American Journal of Clinical Oncology | June 25, 2025 | Volume: 48 | Issue: 12 | Pages: 579-599

10.1097/coc.0000000000001222 | PMID 40557604 Get It

Objectives: Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence. Methods: Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents. Results: ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment. Conclusions: This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.
Significance of Common Genetic Variants Associated with Non-Ischaemic Cardiomyopathy in the General Population
Paldino, Alessia , Figueiral, Marta , Vyas, Hridyanshu , Jenkins, Gregory D. , Batzler, Anthony , Klee, Eric W. , Rodeheffer, Richard J. , Redfield, Margaret M. , Burnett, John C. , Lopez‐Jimenez, Francisco, Sinagra, Gianfranco, Merlo, Marco, Pereira, Naveen L. , Jenkins, Gregory, Medina Inojosa, Jose R, Pereira, Naveen L , Scott, Christopher G. , Medina‐Inojosa, José R. , López-Jiménez, Francisco , Sinagra, Gianfranco , Merlo, Marco

Mayo Clinic

European Journal of Heart Failure | June 23, 2025 | Volume: 27 | Issue: 12 | Pages: 3235-3242

10.1002/ejhf.3724 | PMID 40549485 Get It

ABSTRACT Aims Common genetic variants have been linked to an increased risk of non-ischaemic cardiomyopathy (NICM). The primary objective of this study was to evaluate the significance of these variants in a general population. Methods and results Thirteen NICM risk alleles, previously validated by meta-analyses of case-control genetic association studies, were used to determine genetic risk (GR) in a large, unselected cohort (n = 1897) of Olmsted County residents aged >45 years. Clinical and echocardiographic data, with biomarkers, were correlated with this NICM-GR over a median of 16 years of follow-up (interquartile range [IQR] 15–17). There were no significant differences between the study population quartiles, based on NICM-GR, in terms of age (median 61.6 [IQR 53.6–70.4]), sex (48% male), and cardiovascular risk factors. A significant correlation was detected by specific linear-regression models between NICM-GR and left ventricular (LV) ejection-fraction (beta [standard error]: −2.68 [0.68], p < 0.001), LV end-systolic-diameter (0.22 [0.06], p < 0.001), and LV end-diastolic-diameter (0.14 [0.06], p = 0.01). During follow-up, 46 subjects developed NICM. Using a 3:1 matched-cohort of non-NICM versus NICM patients, linear-regression analysis found a significant correlation between NICM-GR and NICM development (odds ratio 2.27, 95% confidence interval 1.06–4.85, p = 0.03). There was no significant association between these variants and heart failure biomarkers (aldosterone, natriuretic peptides, ST2, galectin-3). Conclusions The NICM-GR correlates with LV function and dimension, and subsequent development of NICM in the general population. The lack of correlation of these variants with cardiovascular risk factors and the renin–angiotensin–aldosterone axis or natriuretic peptides suggest different biological mechanisms involved. These findings support the need to explore newer pathophysiologic pathways in the development of NICM.
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysis
Goethe, Eric A. , Almeida, Romulo Augusto Andrade de, Mikula, Anthony L. , Merrell, Kenneth W. , Rose, Peter S. , Karim, S. Mohammed, Linzey, Joseph R. , Szerlip, Nicholas J. , Ghia, Amol J. , Li, Jing , McAleer, Mary Frances, Perni, Subha , Yeboa, D.N. , Rhines, Laurence D. , North, Robert Y. , Almeida, Rômulo Augusto Andrade de , Call-Orellana, Francisco Alfredo , Clarke, Michelle J. , Amini, Behrang , Beckham, Thomas Hendrix , Tom, Martin C. , McAleer, Mary Frances , Wang, Chenyang , Price, Anthony, Alvarez‐Breckenridge, Christopher , Tatsui, Claudio Esteves

Mayo Clinic

Journal of Neurosurgery: Spine | June 20, 2025 | Volume: 43 | Issue: 3 | Pages: 305-312

10.3171/2025.2.spine24770 | PMID 40540799 Get It

OBJECTIVE Spinal stereotactic radiosurgery (SSRS) is an established treatment modality for spinal metastatic disease. A common complication of SSRS is postradiation pathologic fracture. The authors evaluated the risk of pathologic fracture in sacral SSRS. METHODS All patients receiving SSRS in 1 to 5 fractions to 1 or more sacral levels between 2011 and 2020 at participating institutions were included. Demographic, histological, anatomical, and outcome data were obtained from electronic medical records. Data were analyzed using SPSS version 28. RESULTS Of 67 total patients, 50 (74.6%) were men and 17 (25.4%) were women. The most common tumor histologies were prostate adenocarcinoma (n = 16 [23.9%]) and renal cell carcinoma (n = 12 [17.9%]). Median (range) age at treatment was 63 (8–87) years. The mean ± SD (range) number of levels treated was 1.5 ± 0.7 (1–4) levels. Mean ± SD (range) bone density at S1 was 208.0 ± 74.4 (−3.0 to 443.3) Hounsfield units (HUs). Median (range) follow-up was 16.6 (1.5–132) months, median ± SD (range) overall survival was 24 ± 21.0 (1.7–83.3) months, and the 1-year local control rate was 83.6%. Fourteen patients (20.9%) experienced fracture within the radiation field. There was no association between fracture and patient sex (p = 0.32), age (p = 0.40), S1 HU (p = 0.28), tumor location according to Denis classification (p = 0.87), presence of pain (p = 0.66), single versus multifraction radiation (p = 0.44), or number of levels treated (p = 0.52). Patients experiencing in-field progression were more likely to experience fracture (61.5% vs 10.2%, p < 0.001), and patients experiencing fracture had a higher average Spine Instability Neoplastic Score than patients without fracture (5.7 vs 4.3, p = 0.049). Only local control remained as a factor associated with sacral fracture in the multivariate analysis. Of the patients experiencing fracture, 10 (71.4%) were symptomatic and 3 of those (30.0%) underwent post-SSRS surgical intervention. CONCLUSIONS Pathologic fracture may occur after sacral SSRS in a significant number of patients and is significantly associated with failure of local control.
Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
Haupt, Eric C. , Chawla, Neetu , Osuji, Thearis A. , Shen, Ernest , Casperson, Mallory, Kirchhoff, Anne C. , Zebrack, Brad , Laurent, Cecile A. , Keegan, Theresa H.M. , Abrahão, Renata , Ruddy, Kathryn J. , Nichols, Hazel B. , Wernli, Karen J. , Hahn, Erin E , Haupt, Eric C , Chawla, Neetu , Kirchhoff, Anne C , Zebrack, Bradley J , Laurent, Cecile A , Keegan, Theresa H M , Abrahão, Renata , Ruddy, Kathryn J , Chubak, Jessica , Nichols, Hazel B , Wernli, Karen J , Smitherman, Andrew B. , Chubak, Jessica

Mayo Clinic

JCO Oncology Practice | June 20, 2025 | Volume: 22 | Issue: 5 | Pages: 780-792

10.1200/op-24-00886 | PMID 40540706 Get It

PURPOSE Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
Nishimura, Midori Filiz , Haratake, Tomoka , Nishimura, Yoshito , Nishikori, Asami , Sumiyoshi, Remi , Ujiie, Hideki , Kawahara, Yuri, Ueki, Masao , Laczkó, Dorottya , Oksenhendler, Éric , Kawakami, Atsushi , Koga, Tomohiro , Oksenhendler, Eric , Fajgenbaum, David C , van Rhee, Frits , Sato, Yasuharu , Nishimura, Yoshito , Kawahara, Yuri, Fajgenbaum, David C. , Rhee, Frits van

Mayo Clinic

American Journal of Hematology | June 20, 2025 | Volume: 100 | Issue: 9 | Pages: 1502-1512

10.1002/ajh.27743 | PMID 40540535 Get It

ABSTRACTIdiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight the need for an improved classification system integrating clinical and histopathological findings. We aimed to develop an objective histopathological subtyping system for iMCD that closely correlates with the clinical subtypes. Excisional lymph node specimens from 94 Japanese iMCD patients (54 IPL, 28 TAFRO, 12 NOS) were analyzed for five key histopathological parameters: germinal center (GC) status, plasmacytosis, vascularity, hemosiderin deposition, and “whirlpool” vessel formation in GC. Using hierarchical clustering, we visualized subgroups and developed a machine learning‐based decision tree to differentiate the clinical subtypes and validated it in an external cohort of 12 patients with iMCD. Hierarchical cluster analysis separated the IPL and TAFRO cases into mutually exclusive clusters, whereas the NOS cases were interspersed between them. Decision tree modeling identified plasmacytosis, vascularity, and whirlpool vessel formation as key features distinguishing IPL from TAFRO, achieving 91% and 92% accuracy in the training and test sets, respectively. External validation correctly classified all IPL and TAFRO cases, confirming the reproducibility of the system. Our histopathological classification system closely aligns with the clinical subtypes, offering a more precise approach to iMCD subtyping. It may enhance diagnostic accuracy, guide clinical decision‐making for predicting treatment response in challenging cases, and improve patient selection for future research. Further validation of its versatility and clinical utility is required.
Label‐Free Single‐Molecule Immunoassay
Chen, Chao , Zhou, Shuang , Chemerkouh, Mohammad Javad Haji Najafi , Snozek, Christine L.H. , Jiang, Jiapei, Braswell, Brandyn, Chen, C.-H. , Wang, Shaopeng , Chen, Chao , Zhou, Xiaoyan , Ma, Guangzhong , Yang, Eric H. , Wan, Zijian , Zhou, Xinyu , Wang, Shaopeng

Mayo Clinic

Advanced Science | June 20, 2025 | Volume: 12 | Issue: 31 | Pages: No page available

10.1002/advs.202505207 | PMID 40538199 Get It

Abstract Single‐molecule immunoassay is a reliable technique for the detection and quantification of low‐abundance blood biomarkers, which are essential for early disease diagnosis and biomedical research. However, current single‐molecule methods predominantly rely on endpoint detection and necessitate signal amplification via labeling, which brings a variety of unwanted effects, like matrix effect and autofluorescence interference. This study introduces a real‐time mass imaging‐based label‐free single‐molecule immunoassay (LFSMiA). Featuring plasmonic scattering microscopy‐based mass imaging, a 2‐step sandwich assay format enables background reduction, minimization of matrix effect by dynamic tracking of single binding events, and fully leveraging real‐time data for improved measurement precision through a Bayesian Gaussian process model, the LFSMiA enables ultra‐sensitive and direct protein detection at the single‐molecule level in neat blood sample matrices. LFSMiA measurement is demonstrated for interleukin‐6 and prostate‐specific antigen in buffer, undiluted serum, and whole blood with sub‐femtomolar detection limits and eight logs of dynamic ranges. Moreover, comparable performance is achieved with an inexpensive miniaturized setup. To show its translational potential to clinical settings and point‐of‐care diagnostics, N‐terminal pro‐B‐type natriuretic peptide is examined in patient whole blood samples using the LFSMiA and results in a strong linear correlation (r > 0.99) with standard clinical lab results.
Rocky Mountain Spotted Fever–Associated Myocarditis
Lopez, Camily Morales, Zuberi, Eric C. , Monsanto, Michael A. Acevedo, Prada, Libardo Rueda , Cortes, Melissa P. , Monsanto, Michael Acevedo , Rueda Prada, Libardo , Lopez, Camily Morales

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | June 17, 2025 | Volume: 4 | Issue: 6 | Pages: No page available

10.7326/aimcc.2025.0141 Get It

Cardiac Computed Tomography for Prosthetic Heart Valve Assessment. An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the European Soci
Budde, Ricardo P.J. , Faure, M. , Cremer, Paul , Feuchtner, Gudrun , Gonzales, Holly M, Kiefer, Todd L., Leipsic, Jonathon , Nieman, Koen , Williamson, Eric E. , Ballmoos, Moritz C. Wyler von , Salgado, Rodrigo , Faure, Marguerite E , Abbara, Suhny , Alkadhi, Hatem , Cremer, Paul C , Feuchtner, Gudrun M , Gonzales, Holly M , Leipsic, Jonathan , Nieman, Koen , Revels, Jonathan W , Wang, Dee Dee , Williamson, Eric , Salgado, Rodrigo , Budde, Ricardo Peter Jurgen , Revels, Jonathan , Wang, Dee Dee , Zwischenberger, Brittany A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | June 17, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1148/ryct.250231 | PMID 40526484 Get It

Prosthetic heart valve (PHV) dysfunction is increasingly seen due to the increase in the number of PHV that are being implanted worldwide. Cardiac CT imaging has emerged as a valuable tool to assess PHVs and determine the cause of dysfunction. This consensus document first summarizes the available techniques for PHV assessment. Then the use of CT in PHV (dys)function assessment is discussed in detail including consensus statements for correct indications and patient selection for CT assessment of PHVs, image acquisition, reconstruction and measurement protocols and how to interpret and report the CT findings for specific types of PHV dysfunction. This article was published in Journal of Cardiovascular Computed Tomography, Budde RPJ et al, Cardiac computed tomography for prosthetic heart valve assessment: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the European Society of Cardiovascular Radiology (ESCR), the North American Society for Cardiovascular Imaging (NASCI), the Radiological Society of North America (RSNA), the Society for Cardiovascular Angiography & Interventions (SCAI), and the Society of Thoracic Surgeons (STS). The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation may be used when referencing this document. © 2025 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. on behalf of the Society of Cardiovascular Computed Tomography. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). Keywords: Computed Tomography, Valve, Cardiac, Imaging, Dysfunction, Prosthetic